"We started the project as a collaboration, looking for ways to synthesize compounds and connecting them with compounds that might have biological activities," said Dr. Baltas. The long-term nature of the work underscores the difficulty of modern drug discovery, where thousands of iterations are often required to find a single viable candidate.
One of the most critical findings regarding infuzide is its apparent mechanism of action. Preliminary data suggest that the compound kills bacteria in ways that differ significantly from existing classes of antimicrobials. This is a vital characteristic in the fight against AMR; when a drug utilizes a unique pathway to disrupt bacterial life cycles, the pathogens are less likely to possess pre-existing resistance mechanisms. By attacking the bacteria through a "novel front," infuzide may help keep resistance at bay for a longer period than traditional drugs.
In laboratory assessments, the researchers found that infuzide specifically targets bacterial cells, showing a high degree of selectivity. To gauge its real-world potential, the team compared infuzide’s performance against vancomycin. For decades, vancomycin has been the standard of care for treating severe, resistant Gram-positive infections. However, the laboratory tests revealed that infuzide was able to reduce the size of bacterial colonies more quickly and more effectively than the standard-of-care drug.
Beyond the petri dish, the researchers moved to animal models to observe how the compound performed in a living system. In tests involving mice with resistant S. aureus skin infections, infuzide demonstrated a clear ability to reduce the bacterial population within the affected tissue. Perhaps even more encouraging was the observation of synergistic effects. When infuzide was administered in combination with linezolid—another synthetic antibiotic used for serious infections—the reduction in the bacterial population was even more pronounced than when either drug was used alone. This suggests that infuzide could potentially be used as part of a "cocktail" therapy, enhancing the efficacy of existing drugs and providing a multi-pronged attack against stubborn pathogens.
While the results for Gram-positive bacteria are highly promising, the researchers noted that infuzide did not show significant activity against Gram-negative pathogens. Gram-negative bacteria, such as E. coli or Klebsiella pneumoniae, are characterized by a more complex cell wall structure that is notoriously difficult for many antibiotics to penetrate. However, Dr. Baltas indicated that this is not a dead end for the research. The team is already investigating how small structural modifications to the infuzide molecule might allow it to bypass the defenses of Gram-negative bacteria, potentially expanding its spectrum of activity.
Another significant advantage of infuzide lies in its manufacturing process. The researchers were able to synthesize the compound using "green chemistry" principles—specifically, a solvent-free process. Traditional chemical synthesis often requires large amounts of organic solvents, which are not only expensive but also present significant environmental and disposal challenges. By eliminating the need for these solvents, the researchers have created a production method that is both more sustainable and more cost-effective.
